In November 2020, Archer Materials announced its plan to develop a graphene-based lab-on-chip device. Now, the Company provided an update on the progress it has achieved - it demonstrated that it can fabricate nanosize biosensor components of 100-150 nanometer features on silicon wafers.
In the past, prior to Archer utilizing local semiconductor foundry fabrication techniques, it was limited to one sensor per ~1 cm2. Now, with its in-house capability, it has miniaturized key biosensor components to chip-formats on silicon by nanofabrication translating to approx. over 1 million sensor components within a 1 cm2 area.
Archer's CEO, Dr. Mohammad Choucair, said: “Archer has attracted talented technologists to work on a promising, potential solution to a global challenge that has significant socio-economic implications. As we ramp up our biochip development, we will strategically bridge industry capability gaps, and where possible, locally.”
“At Archer, our staff have a proven track record of producing intellectual property that is worth protecting internationally. As we solve for significant technological barriers in our biochip development, the Company will rapidly translate this knowledge into strong IP assets that would underpin high value, long-term commercialization”.
Archer’s biochip design principles involve using proprietary graphene-based materials as integrated circuits, to form the key sensing elements in its lab-on-a-chip technology. The biochip end-use is initially aimed at addressing the complex detection of diseases affecting the respiratory system.